⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ALLO News
Allogene Therapeutics, Inc. Common Stock
Form 8-K
sec.gov
ALLO
Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update
globenewswire.com
ALLO
Allogene Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update
globenewswire.com
ALLO
Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Cemacabtagene Ansegedleucel (Cema-Cel) as First-Line Consolidation Therapy for Large B-Cell Lymphoma
globenewswire.com
ALLO
Allogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Solid Tumors
globenewswire.com
ALLO
Form 8-K
sec.gov
ALLO
Form 8-K
sec.gov
ALLO
Allogene Therapeutics Announces Planned CEO Succession
globenewswire.com
ALLO
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
globenewswire.com
ALLO
Form 8-K
sec.gov
ALLO